en · de · es · fr · pt
creatine-notes.peptides6908.com › Data › Compound Identity And Development History — 2026 Update

Compound Identity And Development History — 2026 Update

By Editorial Desk · published 2026-03-11 · last reviewed 2026-04-09 · Data

Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-09. Where a claim depends on a specific study, the study is described rather than over-claimed.

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

Handling Storage And Analytical Methods

Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.

Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.

Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.

Related pages on this site

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Supporting material

== Uses == Secretin is used in diagnostic tests for pancreatic function; secretin is injected and the pancreatic output can then be imaged with magnetic resonance imaging, a noninvasive procedure, or secretions generated as a result can gathered either through an endoscope or through tubes inserted through the mouth, down into the duodenum. A recombinant human secretin has been available since 2004 for these diagnostic purposes. There were problems with the availability of this agent from 2012 to 2015.

Subsequent research has found that the delayed dopaminergic phase is associated with the highly potent dopamine D4 receptor agonism of LSD's metabolite 13-hydroxy-LSD. The first phase is described as a "psychedelic experience", with "meaningfulness and portentousness" as the primary effects, while the latter phase is "clearly a paranoid state", including feeling "at the least self-centered, and usually suspicious, with ideas of reference or even paranoid convictions". The second phase typically develops about 4 to 6 hours after administration but at times up to 10 hours after administration. Parallels have been drawn between this phase and amphetamine psychosis. There is no indication that similar effects occur with other psychedelics like phenethylamines and simple tryptamines, which lack dopamine receptor agonism. The preceding findings have been described by researchers like Daniel X. Freedman and David E. Nichols.

The Census Bureau's 2006–2010 American Community Survey showed that (in 2010 inflation-adjusted dollars) median household income was $105,625 (with a margin of error of +/− $14,945) and the median family income was $128,382 (+/− $16,732). Males had a median income of $95,795 (+/− $24,665) versus $72,188 (+/− $16,155) for females. The per capita income for the borough was $56,485 (+/− $6,202). About 2.4% of families and 4.0% of the population were below the poverty line, including 1.8% of those under age 18 and 9.4% of those age 65 or over.

Sources: en.wikipedia.org

Notes from published material

=== Provisions on agriculture === The law rescinds unobligated IRA funding for the Conservation Stewardship Program, Environmental Quality Incentives Program, Agricultural Conservation Easements Program, and Regional Conservation Partnership Program, and adds it to the USDA budget baseline. The OBBBA outlaws climate action-related goals for agriculture. The law also lifts income caps on households that rely on agriculture for more than 75% of their income, potentially empowering corporate farming. The law raises reference prices under the Price Loss Coverage and Agricultural Risk Coverage programs, resulting in $54 billion in additional spending over 10 years. The law increases spending on crop insurance programs by $6.3 billion over 10 years and disaster relief programs at USDA by $2.9 billion in the same timeframe.

=== Tenerife === Upon landing on Tenerife, Humboldt and Bonpland were received by local officials and noted the distinctive flora of the island, including bananas, papaws, and ornamental plants. On June 20, before dawn,Bonpland an Humboldt departed with guides and mules for La Orotava, near the Teide volcano. They passed through San Cristébal, built on a basalt ridge around the Peak of Tenerife, and paused to inspect rocks, eventually arriving at La Laguna, the capital of Tenerife. After the climbing Humboldt and his party left La Laguna, traversing a landscape rich in plant diversity, including palms, orange trees, vines, and cacti. The region’s natural beauty was contrasted by socio-economic inequality, with land concentrated among a few wealthy planters and the indigenous population living in poverty. The group passed through Juan de la Rambla, Victoria, and Matanza, sites of both agricultural abundance and historical conflict with Spanish conquest in the fifteenth century. In La Orotava, they visited the botanical garden and met Monsieur LeGros, the French vice-consul, who had lived on Tenerife since being shipwrecked and agreed to guide their ascent of Pico del Teide. On 21 June 1799, the climbing party, which included LeGros, other local guides, and consular staff, departed for the volcano. The route passed solidly built but somber towns, lush gardens, and a renowned dragon tree, a species present in the Canaries but native to the West Indies, illustrating the complexities of plant distribution.

Role of skin in locomotion describes how the integumentary system is involved in locomotion. Typically the integumentary system can be thought of as skin, however the integumentary system also includes the segmented exoskeleton in arthropods and feathers of birds. The primary role of the integumentary system is to provide protection for the body. However, the structure of the skin has evolved to aid animals in their different modes of locomotion. Soft bodied animals such as starfish rely on the arrangement of the fibers in their tube feet for movement. Eels, snakes, and fish use their skin like an external tendon to generate the propulsive forces need for undulatory locomotion. Vertebrates that fly, glide, and parachute also have a characteristic fiber arrangements of their flight membranes that allows for the skin to maintain its structural integrity during the stress and strain experienced during flight.

== Signs and symptoms == Physical symptoms of CMRD involving the development and function of the gastrointestinal tract and nervous system typically manifest between infancy and adolescence. The symptoms of CmRD are similar to the physical symptoms of malnutrition, as the disease arises due to the poor absorption of lipids and fat-soluble nutrients such as vitamin E. For this reason, the disease is likely to be underdiagnosed by physicians. Fat-soluble nutrients are essential for growth, development, and normal bodily function. Vitamin E deficiency is especially serious, as the vitamin is necessary for proper neurological function and development. Without Vitamin E, neurons cannot operate correctly and signals from the brain are weakened. This leads to reduced muscle development and reduced muscle contraction. Symptoms that manifest in the GI tract are likely to be a consequence of both reduced absorption of fats and physiological stress imposed on enterocytes that can not shuttle fats into circulation. Additional symptoms that occur throughout the body can be attributed to the lack of sufficient lipid sources.

Sources: en.wikipedia.org

Further detail

== Leukotrienes in asthma == Leukotrienes contribute to the pathophysiology of asthma, especially in patients with aspirin-exacerbated respiratory disease (AERD), and cause or potentiate the following symptoms:

=== 2006–2016: Big Love and final roles === In 2006, Chase secured the role of Rhonda Volmer in Big Love, a critically acclaimed drama series on HBO which centered on a polygamist family in Utah led by patriarch Bill Henrickson (Bill Paxton). Chase's character, Rhonda, was introduced as the teenage child bride of the compound's ruthless prophet, Roman Grant (Harry Dean Stanton). Chase remained a recurring and main presence on the series until its conclusion in 2011, earning praise for her chilling depiction of a young woman corrupted by religious extremism. Also in 2006, Chase voiced Lilo for the final time in Leroy & Stitch, the conclusion to the Lilo & Stitch television series. In 2008, she took on the voice role of Betsy in the PBS Kids educational animated series Betsy's Kindergarten Adventures. In 2009, Chase reprised her Donnie Darko role as Samantha in the sequel S. Darko. Set seven years after the events of the original film, the narrative follows an 18-year-old Samantha on a cross-country road trip to Los Angeles, where she becomes plagued by bizarre visions and time anomalies. Unlike its predecessor, S. Darko received overwhelmingly negative reviews from critics. Having been made without the approval of (nor input from) the original film's creator, Richard Kelly, the sequel shares minimal continuity with its predecessor. During the 2010s, Chase appeared primarily in independent thriller and horror films. She played a supporting role in the drama Yellow (2012) and starred in the independent thriller Killer Crush (2015).

=== Synthetic polymers === ECD studies of polyalkene glycols, polyamides, polyacrylates and polyesters are useful for understanding composition of polymer samples. It has become a powerful technique to analyze structural information about precursor ions during MS/MS for synthetic polymers. ECD's single bond cleavage tendency makes the interpretation of product ion scans simple and easy for polymer chemistry.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network